Cargando…

BRCAness in prostate cancer

Detalles Bibliográficos
Autores principales:	Bednarz-Knoll, Natalia, Eltze, Elke, Semjonow, Axel, Brandt, Burkhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497433/ https://www.ncbi.nlm.nih.gov/pubmed/31069005 http://dx.doi.org/10.18632/oncotarget.26818

Ejemplares similares

Low Numbers of Vascular Vessels Correlate to Progression in Hormone-Naïve Prostate Carcinomas Undergoing Radical Prostatectomy
por: Smentoch, Julia, et al.
Publicado: (2019)

EGFR as a stable marker of prostate cancer dissemination to bones
por: Nastały, Paulina, et al.
Publicado: (2020)

Low Tumor-to-Stroma Ratio Reflects Protective Role of Stroma against Prostate Cancer Progression
por: Nastały, Paulina, et al.
Publicado: (2021)

Genome-Wide Investigation of Multifocal and Unifocal Prostate Cancer—Are They Genetically Different?
por: Ibeawuchi, Chinyere, et al.
Publicado: (2013)

AURKA inhibition mimics BRCAness
por: Hirst, Jeff, et al.
Publicado: (2017)

Exploring Prostate Cancer Genome Reveals Simultaneous Losses of PTEN, FAS and PAPSS2 in Patients with PSA Recurrence after Radical Prostatectomy
por: Ibeawuchi, Chinyere, et al.
Publicado: (2015)

CMDX©-based single source information system for simplified quality management and clinical research in prostate cancer
por: Eminaga, Okyaz, et al.
Publicado: (2012)

The BRCAness Landscape of Cancer
por: Guo, Maoni, et al.
Publicado: (2022)

Combining enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness
por: Thompson, Timothy C., et al.
Publicado: (2017)

Clinical map document based on XML (cMDX): document architecture with mapping feature for reporting and analysing prostate cancer in radical prostatectomy specimens
por: Eminaga, Okyaz, et al.
Publicado: (2010)

Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness
por: Tutt, A
Publicado: (2018)

Inhibition of poly (ADP-Ribose) polymerase: A promising strategy targeting pancreatic cancer with BRCAness phenotype
por: Jeong, Keun-Yeong, et al.
Publicado: (2021)

BRCAness Profile of Sporadic Ovarian Cancer Predicts Disease Recurrence
por: Wysham, Weiya Z., et al.
Publicado: (2012)

BRCAness as a prognostic indicator in patients with early breast cancer
por: Liu, Lei, et al.
Publicado: (2020)

Recurrent Ovarian Cancer with BRCAness Phenotype: A Treatment Challenge
por: Caeiro, Cláudia, et al.
Publicado: (2022)

Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness
por: Darbeheshti, Farzaneh, et al.
Publicado: (2022)

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme
por: Xavier, Mary-Ann, et al.
Publicado: (2021)

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Tanino, Hirokazu, et al.
Publicado: (2016)

Using next‐generation sequencing to redefine BRCAness in triple‐negative breast cancer
por: Lin, Po‐Han, et al.
Publicado: (2020)

Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use
por: Abbotts, Rachel, et al.
Publicado: (2022)

Development of a novel BRCAness score that predicts response to PARP inhibitors
por: Oshi, Masanori, et al.
Publicado: (2022)

Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample
por: Yoshida, Reiko, et al.
Publicado: (2021)

Let-7i Reduces Aggressive Phenotype and Induces BRCAness in Ovarian Cancer Cells
por: Chirshev, Evgeny, et al.
Publicado: (2021)

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
por: Lips, E H, et al.
Publicado: (2013)

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness
por: Holme, Harriett, et al.
Publicado: (2018)

DNA methylation-based classifier and gene expression signatures detect BRCAness in osteosarcoma
por: Barenboim, Maxim, et al.
Publicado: (2021)

Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes
por: Tsyganov, Matvey Mihajlovich, et al.
Publicado: (2022)

HIS-based electronic documentation can significantly reduce the time from biopsy to final report for prostate tumours and supports quality management as well as clinical research
por: Breil, Bernhard, et al.
Publicado: (2009)

Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness
por: Holme, Harriett, et al.
Publicado: (2018)

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics
por: Engert, Florian, et al.
Publicado: (2016)

A ribosomal gene panel predicting a novel synthetic lethality in non-BRCAness tumors
por: Zhang, Chao, et al.
Publicado: (2023)

BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer
por: Mori, Hitomi, et al.
Publicado: (2016)

Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness
por: Andersen, Lars v. B., et al.
Publicado: (2023)

Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer
por: Zhang, Yue, et al.
Publicado: (2023)

Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies
por: Stok, Colin, et al.
Publicado: (2021)

Mucosal Scalping of a Subepithelial Lesion: A Naked Colonic Lymphangioma
por: Zimmer, Vincent, et al.
Publicado: (2019)

BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer
por: Lips, Esther H., et al.
Publicado: (2020)

BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study
por: Kosaka, Yoshimasa, et al.
Publicado: (2020)

Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer
por: Schlack, Katrin, et al.
Publicado: (2016)

miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype
por: Tommasi, Stefania, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4nrldsbklldiki24lrqi0h4v8d